European Commission logo
English English
CORDIS - EU research results

Translational Research Network in Prostate Cancer

Project description

Research training network in incurable prostate cancer

Prostate cancer (PC) is a global health concern, and the treatment in cases of resistant cancer relapse following previous hormone therapy remains a challenge. The Marie Skłodowska-Curie Actions-funded TransPot project is a research training network designed to study incurable PC. The objective of the network is to provide training for a group of young researchers to become translational scientists in cancer biology, biomarker discovery, and therapeutic development. The goals include gaining a better understanding of treatment-resistant PC, identifying new strategies to overcome resistance, developing new tests to predict cancer response to treatment, and defining holistic tools for individual patients with treatment-resistant PC.


The Translational Research Network for Prostate Cancer (TransPot) program adopts an innovative, multidisciplinary approach, providing highly sought-after, effective solutions for incurable prostate cancer (PC).

The TransPot scientific objective is to obtain an unmatched depth of molecular, mechanistic and informatics systems-level disease understanding in order to improve the prognosis and treatment of lethal PC, aimed to (i) provide important insights into molecular mechanisms driving treatment resistant PC including castrate-resistant PC (CRPC), (ii) identify novel therapeutic targets, (iii) develop and validate predictive models for disease progression, prognosis and responsiveness to current and novel (co-)treatment options, and (iv) provide superior, clinically relevant tools and biomarker signatures for personalising and optimising CRPC therapy.

Our research program is built on network-wide, state-of-the-art cancer biology-based mechanistic research integrated with a systems medicine approach:

1. Cancer biology-based mechanistic research incorporating a comprehensive range of model systems incorporating unique, pre-clinical and clinical resources and distinct phenotypic high content screen platforms.

2. A systems medicine approach with mathematical modelling to develop novel predictive/prognostic tools.

3. Centres of excellence in surgery, oncology and clinical trials, comprising clinical infrastructure and essential resources whereby candidate therapeutic targets and predictive/prognostic tools can be comprehensively evaluated, including accessing bio-repository resources.

We will train young scientists to apply multiple ‘omics’ technologies and approaches in model systems and systems biology to answer important clinically-relevant questions. Advances achieved will facilitate personalized targeted-medicine in treating lethal PC, and will impact beyond the scientific community by improving the well-being of advanced PC patients.


Net EU contribution
€ 273 287,88
G12 8QQ Glasgow
United Kingdom

See on map

Scotland West Central Scotland Glasgow City
Activity type
Higher or Secondary Education Establishments
Total cost
€ 273 287,88

Participants (10)

Partners (6)